Ultragenyx and Kyowa Kirin Announce Submission of Supplemental Biologics License Application to U.S. FDA for Crysvita® (burosumab) for Tumor-Induced Osteomalacia (TIO)
Go back to Ultragenyx and Kyowa Kirin Announce Submission of Supplemental Biologics License Application to U.S. FDA for Crysvita® (burosumab) for Tumor-Induced Osteomalacia (TIO)| ULTRAGENYX PHARM (NASDAQ: RARE) | Delayed: 35.63 +1.93 (5.73%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $33.70 | 52 Week High | $117.12 | |||
| Open | $34.19 | 52 Week Low | $46.52 | |||
| Day High | $36.57 | P/E | N/A | |||
| Day Low | $33.57 | EPS | $-1.97 | |||
| Volume | 2,719,388 | |||||
